- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00003098
Diet and Estrogen Metabolism in Postmenopausal Women
RATIONALE: The amount of dietary fat or fiber may affect estrogen metabolism in postmenopausal women, and this may affect the risk of developing cancer.
PURPOSE: Randomized dietary intervention to study the effectiveness of a low-fat diet combined with either high fiber or low fiber on estrogen metabolism in healthy postmenopausal women.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES: I. Determine the effect of a low fat diet combined with either high fiber (25-35 grams per day) or low fiber (10-15 grams per day) intake on estrogen metabolism in healthy postmenopausal women.
OUTLINE: This is a randomized study. Patients are randomized to one of 2 arms (dietary fat reduction with and without increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
PROJECTED ACCRUAL: 40 women will be accrued over 4 years.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS: Healthy postmenopausal female between the ages of 50 and 69 with diet of greater than 32% of total calories from fat and less than 15 grams of fiber
PATIENT CHARACTERISTICS: Age: 50 to 69 Sex: Female Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: At least 2 years since menopause In general good health Increased body fat (125%-175% of ideal body weight) Increased upper body fat (waist-to-hip circumference ratio greater than 0.85) Serum estradiol greater than 13 picograms per milliliter
PRIOR CONCURRENT THERAPY: No concurrent medication that can interfere with blood test results No hormone replacement therapy or thyroid hormones
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: fat reduction increased fiber
Patients are randomized to dietary fat reduction with increased fiber).
All patient must successfully complete a dietary run-in phase for 4 weeks before randomization.
During the run-in phase, patients are asked to maintain a food record for days 7-14.
Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28.
Patients are given 3 prepackaged meals a day for 12 weeks.
Patients must maintain a record of all food eaten and return all food containers to the center for documentation.
Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84.
At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
|
Patients are randomized to dietary fat reduction with increased fiber.
All patient must successfully complete a dietary run-in phase for 4 weeks before randomization.
During the run-in phase, patients are asked to maintain a food record for days 7-14.
Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28.
Patients are given 3 prepackaged meals a day for 12 weeks.
Patients must maintain a record of all food eaten and return all food containers to the center for documentation.
Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84.
At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
|
|
Experimental: fat reduction without increased fiber
Patients are randomized to dietary fat reduction without increased fiber).
All patient must successfully complete a dietary run-in phase for 4 weeks before randomization.
During the run-in phase, patients are asked to maintain a food record for days 7-14.
Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28.
Patients are given 3 prepackaged meals a day for 12 weeks.
Patients must maintain a record of all food eaten and return all food containers to the center for documentation.
Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84.
At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
|
Patients are randomized to dietary fat reduction without increased fiber.
All patient must successfully complete a dietary run-in phase for 4 weeks before randomization.
During the run-in phase, patients are asked to maintain a food record for days 7-14.
Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28.
Patients are given 3 prepackaged meals a day for 12 weeks.
Patients must maintain a record of all food eaten and return all food containers to the center for documentation.
Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84.
At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: David Heber, MD, Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000065828
- UCLA-HSPC-950942302 (Other Identifier: UCLA)
- NCI-P97-0112 (Other Identifier: PDQ Idenifier)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
Clinical Trials on fat reduction with increased fiber
-
University Hospital TuebingenCompletedType 2 Diabetes Mellitus | Liver Fat | Insulin Sensitivity | Nutritional and Metabolic DiseasesGermany
-
Tel-Aviv Sourasky Medical CenterUnknownObesity | Diabetes Mellitus, Type 2Israel
-
Washington University School of MedicineCompletedMicrobiota | Gastrointestinal MicrobiomeUnited States
-
University of ChicagoRecruiting
-
Stanford UniversityActive, not recruiting
-
Syneron MedicalUnknownUnwanted Thigh FatUnited States
-
Syneron MedicalSuspendedUnwanted Flanks Fat
-
Clinical Nutrition Research Center, Illinois Institute...Hass Avocado BoardCompleted
-
University of Massachusetts, WorcesterAmerican Cancer Society, Inc.Completed